Ani Pharmaceuticals (ANIP) Assets Average (2011 - 2026)

Ani Pharmaceuticals has disclosed Assets Average across 16 years of filings, most recently posting $1.4 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $1.4 billion, up 11.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 11.08% YoY), and the FY2025 annual result was $1.4 billion, up 24.49% from the prior year.
• Assets Average came in at $1.4 billion for Q1 2026 at Ani Pharmaceuticals, roughly flat from $1.4 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2026 to a low of $745.2 million in Q3 2022.
• The 5-year median for Assets Average is $909.5 million (2024), against an average of $1.0 billion.
• Across the five-year window, Assets Average soared 63.93% in 2022 and climbed 0.58% in 2023, its largest moves.
• Ani Pharmaceuticals' Assets Average stood at $749.6 million in 2022, then gained by 19.69% to $897.2 million in 2023, then soared by 43.33% to $1.3 billion in 2024, then grew by 10.76% to $1.4 billion in 2025, then increased by 0.49% to $1.4 billion in 2026.
• The last three Assets Average figures came in at $1.4 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.